Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique - 2How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- 3The most effective method to Keep up with Proficient Handshakes in a Computerized World
- 4James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- 5Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- UN mission says no evidence Hezbollah rearming in southern Lebanon
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Emotional wellness Matters: My Fight with Tension
- Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
- Gauging the Upsides and downsides of Visas: A Complete Aide
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- Heart disease risk greater for women with a common condition they may not be aware they have
